<?xml version="1.0" encoding="UTF-8"?>
<p id="p0240">Next, sofosbuvir (SBV) 
 <bold>(14)</bold> is an example of successful nucleotide prodrug, approved by the Food Drug Administration (FDA) since 2013, against chronic hepatitis C infections. SBV is also combined with other antiviral drugs, such as ledipasvir, velpatasvir and voxilaprevir.
 <xref rid="b0550" ref-type="bibr">110</xref>, 
 <xref rid="b0555" ref-type="bibr">111</xref> The structural similarity between SBV (
 <xref rid="f0015" ref-type="fig">Fig. 3</xref>) and uridine allows that drug to act on HCV RdRp, incorporate itself into the viral RNA and terminate the synthesis of the nucleotide sequence.
 <xref rid="b0405" ref-type="bibr">
  <sup>81</sup>
 </xref> Structural analysis of SBV revealed that its elevated potential is partly due to the presence of the 5â€²-phosphate, which terminates the primary enzyme transformation monophosphate inhibitor.
 <xref rid="b0560" ref-type="bibr">
  <sup>112</sup>
 </xref> The antiviral activity has been explored against other viruses through 
 <italic>in-vitro</italic> and 
 <italic>in-silico</italic> studies and shown potential for inhibiting the dengue virus,
 <xref rid="b0565" ref-type="bibr">
  <sup>113</sup>
 </xref> yellow fever,
 <xref rid="b0570" ref-type="bibr">
  <sup>114</sup>
 </xref> zika virus,
 <xref rid="b0575" ref-type="bibr">
  <sup>115</sup>
 </xref> and chikungunya virus.
 <xref rid="b0580" ref-type="bibr">
  <sup>116</sup>
 </xref>
</p>
